Aravive Management

Management criteria checks 2/4

Aravive's CEO is Gail McIntyre, appointed in Apr 2020, has a tenure of 3.42 years. total yearly compensation is $1.58M, comprised of 32.3% salary and 67.7% bonuses, including company stock and options. directly owns 0.092% of the company’s shares, worth $9.76K. The average tenure of the management team and the board of directors is 3.1 years and 3.2 years respectively.

Key information

Gail McIntyre

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage32.3%
CEO tenure3.4yrs
CEO ownership0.09%
Management average tenure3.1yrs
Board average tenure3.2yrs

Recent management updates

Recent updates

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Apr 26
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Sep 03
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Aravive Q2 GAAP EPS misses, revenue beats

Aug 11

Aravive appoints Robert Geller as CMO

Jul 05

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

May 15
We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Nov 06
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Jun 25
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive EPS beats by $0.01, misses on revenue

May 06

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Apr 27

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18
Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive: Pipeline-In-A-Pill In Oncology

Dec 28

Aravive (ARAV) Investor Presentation - Slideshow

Dec 04

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative

Nov 19

Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China

Nov 10

CEO Compensation Analysis

How has Gail McIntyre's remuneration changed compared to Aravive's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2023n/an/a

-US$77m

Mar 31 2023n/an/a

-US$113m

Dec 31 2022US$2mUS$510k

-US$76m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$2mUS$500k

-US$39m

Sep 30 2021n/an/a

-US$30m

Jun 30 2021n/an/a

-US$30m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020US$1mUS$404k

-US$31m

Sep 30 2020n/an/a

-US$31m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$24m

Dec 31 2019US$713kUS$325k

-US$18m

Sep 30 2019n/an/a

-US$65m

Jun 30 2019n/an/a

-US$65m

Mar 31 2019n/an/a

-US$72m

Dec 31 2018US$101kUS$59k

-US$76m

Compensation vs Market: Gail's total compensation ($USD1.58M) is above average for companies of similar size in the US market ($USD764.66K).

Compensation vs Earnings: Gail's compensation has increased whilst the company is unprofitable.


CEO

Gail McIntyre (60 yo)

3.4yrs

Tenure

US$1,580,639

Compensation

Dr. Gail F. McIntyre, Ph D., CH (ASCP), DABT, serves as President, Chief Executive Officer and Director at Aravive, Inc. since April 08, 2020 and served as its Chief Scientific Officer since February 12, 2...


Leadership Team

NamePositionTenureCompensationOwnership
Fredric Eshelman
Executive Chairman3.4yrsUS$170.00k0%
$ 0
Gail McIntyre
President3.4yrsUS$1.58m0.092%
$ 9.8k
Rudy Howard
Chief Financial Officer1.3yrsUS$798.88k0.015%
$ 1.6k
Jeffrey Cleland
Co-Founderno dataUS$669.98kno data
Joshua Silverman
Co-Founder15.7yrsno datano data
Marek Ciszewski
Vice President of Investor Relationsno datano datano data
Randy Anderson
Senior Vice President of Data Sciences3.1yrsno datano data

3.1yrs

Average Tenure

62.5yo

Average Age

Experienced Management: ARAV's management team is considered experienced (3.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Fredric Eshelman
Executive Chairman3.4yrsUS$170.00k0%
$ 0
Gail McIntyre
President3.4yrsUS$1.58m0.092%
$ 9.8k
Michael Rogers
Independent Director3yrsUS$167.50k0%
$ 0
Sigurd Kirk
Independent Director2.3yrsUS$147.50k0%
$ 0
Amato Giaccia
Independent Director4.9yrsUS$162.50k1.65%
$ 174.3k
T. Ho
Independent Director2.3yrsUS$143.50k0.075%
$ 7.9k
John Hohneker
Independent Director2.3yrsUS$145.00k0%
$ 0
Eric Zhang
Independent Director4.9yrsUS$147.50k1.91%
$ 201.5k

3.2yrs

Average Tenure

62yo

Average Age

Experienced Board: ARAV's board of directors are considered experienced (3.2 years average tenure).